Interpace Diagnostics Stock Price - IDXG

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Interpace Diagnostics Group Inc IDXG NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.7884 0.00 0.00 0.00 0.7884 20:00:00
Bid Price Ask Price Spread Spread % News
0.68 0.70 0.02 2.86% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Interpace Diagnostics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 30.11M 38.20M $ -12.19M -0.43 -2.08 35.02M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Interpace Diagnostics News

Loading Messages....

Latest IDXG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IDXG Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week0.84760.8680.7460.7940140k-0.0592-6.98%
1 Month0.7470.8680.70.7612132k0.04145.54%
3 Months0.7251.050.68110.8004175k0.06348.74%
6 Months0.8341.050.660.7650242k-0.0456-5.47%
1 Year1.561.740.660.9836292k-0.7716-49.46%
3 Years0.18914.250.071.57381M0.5994317.14%
5 Years2.4114.250.071.5583773k-1.6216-67.29%

Interpace Diagnostics Description

Interpace Diagnostics Group Inc is a United States-based integrated commercial and bioinformatics company. It is engaged in developing and commercializing molecular diagnostic tests, leveraging the technology and personalized medicine for patient diagnosis and management. The company has four commercialized molecular tests, PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts, ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay and, ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay, and RespriDX for assessing metastatic versus primary lung cancer tumors. The company's customers consist of physicians, hospitals, and clinics.

Your Recent History
Interpace ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.